Scinai Immunotherapeutics Announces The Establishment Of A U.S.-Based Subsidiary For Its Contract Development And Manufacturing Services
Scinai Immunotherapeutics Announces The Establishment Of A U.S.-Based Subsidiary For Its Contract Development And Manufacturing Services
Scinai免疫治疗公司宣布在美国建立一家子公司，以提供其合同开发和制造服务。
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced today the establishment of a U.S.-based subsidiary for its Contract Development and Manufacturing Services. The new subsidiary, incorporated in Delaware, will operate under the name Scinai Bioservices Inc.
Scinai免疫治疗有限公司（纳斯达克：SCNI）（“Scinai”或“公司”）是一家专注于开发炎症和免疫学（I&I）生物产品以及通过其Scinai Bioservices业务部门提供CDMO服务的生物制药公司，今天宣布在美国建立一家子公司，提供合同开发和制造服务。这家新子公司注册在特拉华州，将以Scinai Bioservices Inc.的名义运营。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。